HER2-Low Status Is Not Accurate in Breast Cancer Core Needle Biopsy Samples: An Analysis of 5610 Consecutive Patients

SIMPLE SUMMARY: Novel anti-HER2 antibody–drug conjugates showed convincing efficacy in HER2-Low breast cancer patients. We aimed to investigate the accuracy of core needle biopsy (CNB) in diagnosing HER2-Low status. We found a low concordance rate of HER2-Low status between CNB and surgical excision...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yujie, Zhu, Siji, Tong, Yiwei, Fei, Xiaochun, Jiang, Wu, Shen, Kunwei, Chen, Xiaosong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777154/
https://www.ncbi.nlm.nih.gov/pubmed/36551684
http://dx.doi.org/10.3390/cancers14246200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777154/
https://www.ncbi.nlm.nih.gov/pubmed/36551684
http://dx.doi.org/10.3390/cancers14246200

Ejemplares similares